Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

MATCH Treatment Subprotocol Z1H: Phase II Study of Copanlisib in Patients With Tumors With Deleterious PTEN Sequencing Result and PTEN Expression by IHC

NCT06400238 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT06400238
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06400238 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
MATCH Treatment Subprotocol Z1H: Phase II Study of Copanlisib in Patients With Tumors With Deleterious PTEN Sequencing Result and PTEN Expression by IHC
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Active, not recruiting
Start date
October 15, 2018
Completion date
December 31, 2026
Enrollment
35 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced lymphoma, advanced malignant solid neoplasm, refractory lymphoma, refractory malignant solid neoplasm, refractory multiple myeloma